Back to Search Start Over

HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

Authors :
Cheng J
Pan J
Zhao D
Ma X
Sun Q
Li J
Source :
International Medical Case Reports Journal, Vol Volume 17, Pp 121-124 (2024)
Publication Year :
2024
Publisher :
Dove Medical Press, 2024.

Abstract

Jun Cheng,* Jinjin Pan,* Dongmei Zhao, Xuejiao Ma, Qiulin Sun, Jiabin Li Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jiabin Li, Tel/Fax +86-551-62922281, Email lijiabin@163.comAbstract: The global prevalence of hepatitis C virus (HCV) infection is approximately 3%, with a post-infection chronicity rate of up to 50%– 85%. HCV reactivation can occur when anti-HCV positive individuals receive antineoplastic therapy. In this study, we report a case of an anti-HCV positive patient with negative HCV RNA after 12 weeks of direct antiviral therapy. Two months later, sorafenib was used to treat hepatocellular carcinoma, and HCV reactivation occurred after 8 months of the treatment. HCV RNA was negative after 12 weeks of antiviral treatment with Sofosbuvir-velpatasvir. We also discussed the mechanism of HCV reactivation caused by sorafenib and the antiviral treatment regimen after HCV reactivation with the relevant literature.Keywords: hepatocellular carcinoma, sorafenib, HCV-RNA, anti-HCV therapy, reactivation

Details

Language :
English
ISSN :
1179142X
Volume :
ume 17
Database :
Directory of Open Access Journals
Journal :
International Medical Case Reports Journal
Publication Type :
Academic Journal
Accession number :
edsdoj.13740170825145739da99eacb211d2db
Document Type :
article